Radiofrequency ablation of lung malignancies: Where do we stand?

被引:42
|
作者
Lencioni, R
Crocetti, L
Cioni, R
Mussi, A
Fontanini, G
Ambrogi, M
Franchini, C
Cioni, D
Fanucchi, O
Gemignani, R
Baldassarri, R
Angeletti, CA
Bartolozzi, C
机构
[1] Univ Pisa, Dept Oncol Transplants & Adv Technol Med, Div Diagnost & Intervent Radiol, I-56126 Pisa, Italy
[2] Univ Pisa, Div Thorac Surg, Cardiac & Thorac Dept, I-56127 Pisa, Italy
[3] Univ Pisa, Div Pathol, Dept Oncol Transplatn & Adv Technol Med, I-56126 Pisa, Italy
[4] Cisanello Univ Hosp, Div Anesthesiol, I-56127 Pisa, Italy
关键词
lung neoplasms; metastases; therapy; radiofrequency ablation;
D O I
10.1007/s00270-004-0008-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Percutaneous radiofrequency (RF) ablation is a minimally invasive technique used to treat solid tumors. Because of its ability to produce large volumes of coagulation necrosis in a controlled fashion, this technique has gained acceptance as a viable therapeutic option for unresectable liver malignancies. Recently, investigation has been focused on the clinical application of RF ablation in the treatment of lung malignancies. In theory, lung tumors are well suited to RF ablation because the surrounding air in adjacent normal parenchyma provides an insulating effect, thus facilitating energy concentration within the tumor tissue. Experimental studies in rabbits have confirmed that lung RF ablation can be safely and effectively performed via a percutaneous, transthoracic approach, and have prompted the start of clinical investigation. Pilot clinical studies have shown that RF ablation enables successful treatment of relatively small lung malignancies with a high rate of complete response and acceptable morbidity, and have suggested that the technique could represent a viable alternate or complementary treatment method for patients with non-small cell lung cancer or lung metastases of favorable histotypes who are not candidates for surgical resection. This article gives an overview of lung RF ablation. discussing experimental animal findings, rationale for clinical application, technique and methodology, clinical results, and complications.
引用
收藏
页码:581 / 590
页数:10
相关论文
共 50 条
  • [1] Radiofrequency Ablation of Lung Malignancies: Where Do We Stand?
    Riccardo Lencioni
    Laura Crocetti
    Roberto Cioni
    Alfredo Mussi
    Gabriella Fontanini
    Marcello Ambrogi
    Chiara Franchini
    Dania Cioni
    Olivia Fanucchi
    Raffaello Gemignani
    Rubia Baldassarri
    Carlo Alberto Angeletti
    Carlo Bartolozzi
    [J]. CardioVascular and Interventional Radiology, 2004, 27 : 581 - 590
  • [2] Lung Tumor Radiofrequency Ablation: Where Do We Stand?
    Thierry de Baère
    [J]. CardioVascular and Interventional Radiology, 2011, 34 : 241 - 251
  • [3] Lung Tumor Radiofrequency Ablation: Where Do We Stand?
    de Baere, Thierry
    [J]. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2011, 34 (02) : 241 - 251
  • [4] Hematologic Malignancies: Where Do We Stand in 2011?
    Kantarjian, Hagop
    Schiffer, Charles
    Burnett, Alan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) : 473 - 474
  • [5] Prevention initiative for dermatological malignancies: where do we stand?
    Stockfleth, E.
    Hinrichs, B.
    Surber, C.
    Christophers, E.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 : V - VI
  • [6] Laparoscopic lymphadenectomy for gynecological malignancies - Where do we stand?
    Lecuru, F
    Robin, F
    Taurelle, R
    [J]. CANCER JOURNAL - FRANCE, 1998, 11 (04): : 208 - 214
  • [7] Haploidentical transplantation for hematologic malignancies: where do we stand?
    Fuchs, Ephraim J.
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2012, : 230 - 236
  • [8] Atrial Fibrillation Ablation in Octogenarians: Where Do We Stand?
    Gevorg Stepanyan
    Edward P. Gerstenfeld
    [J]. Current Cardiology Reports, 2013, 15
  • [9] Atrial Fibrillation Ablation in Octogenarians: Where Do We Stand?
    Stepanyan, Gevorg
    Gerstenfeld, Edward P.
    [J]. CURRENT CARDIOLOGY REPORTS, 2013, 15 (10)
  • [10] Ablation for Hepatocellular Carcinoma: Where Do We Stand? Reply
    Liu, Po-Hong
    Huo, Teh-Ia
    [J]. ANNALS OF SURGERY, 2017, 266 (06) : E55 - E56